

# Working Groups Overview

*A Path for the Ocular Diseases Forum*

**Sehyr Khan, BA**

Forum for Collaborative Research

UC Berkeley School of Public Health

# Working Groups Overview

- The main arm in which key questions are answered and consensus is driven
- Each WG focus on a particular need of the ODF and are typically led by academic and industry co-chairs
- Outputs:
  - Consensus papers, manuscripts, white papers, and commentaries

# Working Groups Participation

- Open to all stakeholders with expertise in inherited retinal diseases, macular degeneration, gene and cell therapy, and diagnostics
- Organizations can nominate participants whose skills could contribute to the working group's outputs
- WGs communicate and collaborate by conference calls, email, virtual and in-person meetings, and workshops as needed
- Members are expected to be active participants and participate in as many calls and activities as possible

# Endpoint and Periodicity of Clinical Trials


*Address the question; How shall we determine an endpoint? How do we understand the purpose of the drug and its mechanism of action?*

# Endpoint Validation

Understand what is necessary to develop and validate an endpoint from a regulatory perspective— *what is needed to validate an endpoint?*

# Patient Experience

Address issues regarding patient experience: patient safety, treatment of the second eye and treatment following adverse events.



**Interested in participating? Contact us!**

**Thank You**